Phenformin Inhibits the Proliferation of MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines

Year 2023, Volume: 5 Issue: 1, 103 - 6, 15.01.2023

Amra Halugıc Sen , Dilan Çetinavcı , Gürkan Yiğittürk , Ayca Yazıcı , Hülya Elbe , Feral Öztürk

https://doi.org/10.37990/medr.1137136

Abstract

Aim: Breast cancer is the most common malignancy in women. This disease is a critical public health problem and further research at the molecular level would define its prognosis and specific treatment. Phenformin is an antidiabetic agent. Recent studies showed that it should be considered as a potential agent for the prevention and treatment of cancer cell lines. This study aimed to investigate the antiproliferative effect of phenformin on MDA-MB-231 and MCF-7 breast cancer cell lines.
Materials and Methods: MDA-MB-231 and MCF-7 breast cancer cell lines were used in the study. Experimental groups; control group, 1 µM, 2.5 µM, and 5 µM phenformin administered groups were planned. WST-1 analysis was performed to evaluate the viability of cells 24 h after the treatments. Statistical analysis was carried out using the SPSS 17.0 statistical program. p<0.05 was considered to indicate a statistically significant difference.
Results: In the MDA-MB-231 breast cancer cell line, there were statistically significant differences among all groups (p<0.05, for all), except between the 1 µM phenformin-treated and control groups (p>0.05). In the MCF-7 breast cancer cell line; there were statistically significant differences between the control group and 5 µM phenformin-treated, and between 1 µM phenformin-treated and 5 µM phenformin-treated (p<0.05, for all) groups.
Conclusion: Phenformin seems to exert antiproliferative effects on MDA-MB-231 and MCF-7 breast cancer cell lines. It was observed that the antiproliferative effect was stronger in the MDA-MB-231 cell line. It showed a stronger antiproliferative effect in the MDA-MB-231 cell line of antiproliferative effect.

Keywords

Breast cancer, MDA-MB 231, MCF-7, Phenformin

Thanks

The authors extend their sincere gratitude to the Department of Histology and Embryology, Faculty of Medicine, Mugla Sıtkı Kocman University, for their support.

References

• 1. Ozkan M. Psychosocial adaptation during and after breast cancer. Breast Disease. 2019;705-27.
• 2. Sharma GN, Dave R, Sanadya J, et al. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1:109.
• 3. Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer access date 26.03.2021
• 4. Uprety B, Abrahamse H. Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights. Cells. 2022;11:576.
• 5. Trousil S, Chen S, Mu C, et al. Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma. J Invest Dermatol. 2017;137:1135-43.
• 6. Cao Y, Xu S, Xu C, et al. Synthesis, Anticancer Activity and Mechanism of Phenformin Derivatives. Chemistry Select. 2022;7:e202104250.
• 7. García Rubiño ME, Carrillo E, Ruiz Alcalá G, et al. Phenformin as an anticancer agent: challenges and prospects. Int J Mol Sci. 2019;20:3316. 8. Janzer A, German NJ, Gonzalez-Herrera KN, et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci. 2014;111:10574-9.
• 9. Liu Z, Ren L, Liu C, et al. Phenformin induces cell cycle change, apoptosis, and mesenchymal-epithelial transition and regulates the AMPK/mTOR/p70s6k and MAPK/ERK pathways in breast cancer cells. PloS one. 2015;10:e0131207.
• 10. Tu DG, Yu Y, Lee CH, et al. Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome mediated degradation of epidermal growth factor receptor. Oncol lett. 2016;11:2934-40.
• 11. Coperchini F, Croce L, Denegri M, et al. The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes. Oncotarget. 2019;10:6432.
• 12. Miskimins WK, Ahn HJ, Kim JY, et al. Synergistic anti-cancer effect of phenformin and oxamate. PloS one. 2014;9:e85576.
• 13. Zhao W, Zhang X, Liu J, et al. miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. Oncol Rep. 2016;36:3691-9.
• 14. Appleyard MV, Murray KE, Coates PJ, et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer . 2012;106:1117-22.
• 15. Guo Z, Zhao M, Howard EW, et al. Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway. Oncotarget. 2017;8:60342.